Fundraising FoxClover Biopharmaceuticals
Chengdu · Founded 2018 · 1 known investors
Find your way into Clover Biopharmaceuticals
Sign up to see every warm intro you have to Clover Biopharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Clover Biopharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities. Its pipeline focuses on respiratory vaccine candidates, including RSV, hMPV, and PIV3 combinations, for populations worldwide.
Founders & leadership
Clover Biopharmaceuticals was founded in 2018 by Peng Liang.
PL
Peng LiangFounderHe was faculty in the Cancer Biology department at Vanderbilt University from 1995–2010 and conducted postdoctoral research at Harvard Medical School, where he contributed to development of Differential Display technology for gene expression analysis. Liang holds a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign and a B.S. in Biology from Beijing University.
Board
XW
Xiaodong WangBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$53.4M disclosed across 3 rounds · 2021–2026
▶$3.6MraisedApr 2026 · 9 investors · BiotechnologyRule 506(b)
▶$3.6MraisedApr 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peng LiangExecutive Officer, Director, Promoter
- Joshua LiangExecutive Officer, Director
- Xiaodong WangDirector
- Offering amount
- $3.6M
- Amount sold
- $3.6M
- First sale
- Mar 2026
- Incorporated
- Corporation, Cayman Islands
- Federal exemptions
- 06b
▶$904.9KraisedApr 2025 · 13 investors · BiotechnologyRule 506(b)
▶$904.9KraisedApr 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joshua LiangExecutive Officer, Director
- Peng LiangExecutive Officer, Director, Promoter
- Xiaodong WangDirector
- Offering amount
- $904.9K
- Amount sold
- $904.9K
- First sale
- Apr 2024
- Incorporated
- Corporation, Cayman Islands
- Federal exemptions
- 06b
▶$48.9MraisedMay 2023 · 74 investors · BiotechnologyRule 506(b)
▶$48.9MraisedMay 2023 · 74 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peng LiangExecutive Officer, Director, Promoter
- Xiaodong WangDirector
- Joshua LiangExecutive Officer, Director
- Amount sold
- $48.9M
- First sale
- Apr 2021
- Incorporated
- Corporation, Cayman Islands, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Clover HealthClover Health is a health insurance provider offering low-cost plans with minimal premiums, copays, and prescription drug costs. The company uses technology called Clover Assistant to help members focus on healthier living.
VirVir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities. The company targets patients with unmet medical needs across these therapeutic areas.
DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
IconOVir BioIconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
Companies working in the same space as Clover Biopharmaceuticals.
Frequently asked questions
- What does Clover Biopharmaceuticals do?
- Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities. Its pipeline focuses on respiratory vaccine candidates, including RSV, hMPV, and PIV3 combinations, for populations worldwide.
- Who founded Clover Biopharmaceuticals?
- Clover Biopharmaceuticals was founded by Peng Liang in 2018.
- Who are Clover Biopharmaceuticals's investors?
- Clover Biopharmaceuticals's investors include Delos Capital.
- How much funding has Clover Biopharmaceuticals raised?
- Clover Biopharmaceuticals has disclosed $53.4M raised across 3 rounds.
- Where is Clover Biopharmaceuticals headquartered?
- Clover Biopharmaceuticals is headquartered in Chengdu.